A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood …
…, D Walker, D Van Vuurden, E De Carli… - Neuro …, 2013 - academic.oup.com
Astrocytic tumors account for 42% of childhood brain tumors, arising in all anatomical regions
and associated with neurofibromatosis type 1 (NF1) in 15%. Anatomical site determines …
and associated with neurofibromatosis type 1 (NF1) in 15%. Anatomical site determines …
[HTML][HTML] First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in …
…, N André, J Rubino, I Aerts, E De Carli… - European Journal of …, 2021 - Elsevier
Aim Arms E and F of the AcSé-ESMART phase I/II platform trial aimed to define the
recommended dose and preliminary activity of the dual mTORC1/2 inhibitor vistusertib as …
recommended dose and preliminary activity of the dual mTORC1/2 inhibitor vistusertib as …
Phase I or II study of ribociclib in combination with topotecan-temozolomide or everolimus in children with advanced malignancies: arms A and B of the AcSé-ESMART …
…, S Nebchi, N Andre, I Aerts, E De Carli… - Journal of Clinical …, 2021 - ingentaconnect.com
PURPOSE AcSé-ESMART is a proof-of-concept, phase I or II, platform trial, designed to
explore targeted agents in a molecularly enriched cancer population. Arms A and B aimed to …
explore targeted agents in a molecularly enriched cancer population. Arms A and B aimed to …
Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA …
…, S Ducassou, M Strullu, E de Carli… - JAMA Network …, 2023 - jamanetwork.com
Importance Innovative anticancer therapies for children, adolescents, and young adults are
regularly prescribed outside their marketing authorization or through compassionate use …
regularly prescribed outside their marketing authorization or through compassionate use …
Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+ 5
…, N André, C Chappé, P Schneider, E De Carli… - Neuro …, 2021 - academic.oup.com
Background High-risk medulloblastoma is defined by the presence of metastatic disease
and/or incomplete resection and/or unfavorable histopathology and/or tumors with MYC …
and/or incomplete resection and/or unfavorable histopathology and/or tumors with MYC …
[HTML][HTML] Mortality in children with optic pathway glioma treated with up-front BB-SFOP chemotherapy
J Rakotonjanahary, E De Carli, M Delion, C Kalifa… - PLoS …, 2015 - journals.plos.org
Background In terms of overall survival (OS), limited data are available for the very long-term
outcomes of children treated for optic pathway glioma (OPG) with up-front chemotherapy. …
outcomes of children treated for optic pathway glioma (OPG) with up-front chemotherapy. …
VIP hypersecretion as primary or secondary syndrome in neuroblastoma: A retrospective study by the Société Française des Cancers de l'Enfant (SFCE)
F Bourdeaut, E de Carli, S Timsit, C Coze… - Pediatric blood & …, 2009 - Wiley Online Library
Background Neuroblastic tumors (NTs) are occasionally associated with watery diarrhea, due
to Vasoactive Intestinal Peptide (VIP) secretion. Most reports are single cases and suggest …
to Vasoactive Intestinal Peptide (VIP) secretion. Most reports are single cases and suggest …
The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: A retrospective nationwide study in 72 patients
…, N Boddaert, D Figarella-Branger, E De Carli… - Journal of Neuro …, 2022 - Springer
Introduction At least half of children with low-grade glioma (LGG) treated with first line
chemotherapy experience a relapse/progression and may therefore need a second-line …
chemotherapy experience a relapse/progression and may therefore need a second-line …
[HTML][HTML] Phase I study of a combination of fluvastatin and celecoxib in children with relapsing/refractory low-grade or high-grade glioma (FLUVABREX)
…, AI Bertozzi, P Chastagner, N Entz-Werlé, E De Carli… - Cancers, 2023 - mdpi.com
Simple Summary This study tested the repurposing of two rationally selected, non-anticancer
drugs as a way to address the need for less toxic therapeutic options in children with …
drugs as a way to address the need for less toxic therapeutic options in children with …
Phase I/II study of the WEE1 inhibitor adavosertib (AZD1775) in combination with carboplatin in children with advanced malignancies: Arm C of the AcSé-ESMART …
…, S Nebchi, I Aerts, E Thebaud, E De Carli… - Clinical Cancer …, 2024 - AACR
Purpose: AcSé-ESMART Arm C aimed to define the recommended dose and activity of the
WEE1 inhibitor adavosertib in combination with carboplatin in children and young adults with …
WEE1 inhibitor adavosertib in combination with carboplatin in children and young adults with …